Alzheimer’s disease: Despite failures, hope for new treatment by 2025 04-Feb-2019 By Ben Hargreaves Despite Roche’s recent trial failure for crenezumab, the ProMIS team remain confident a disease-modifying treatment will be found in the next decade.
Neurocrine agrees to pay up to $1.7bn in gene therapy collaboration 31-Jan-2019 By Maggie Lynch Neurocrine and Voyager enter an agreement to fund and develop gene therapy candidates for the treatment of severe neurological diseases.
‘A relatively small footprint’: Drug delivery for biologics to the brain 21-Jan-2019 By Maggie Lynch Reaching the central nervous system is a difficult task, and getting a high enough dose to it poses an issue as well, but innovations are well underway to bridge a path across the blood-brain barrier.
